BHB & CAR-T for Lymphomas

Inclusion criteria

• Age of 18 years or older
• History of pathologically-confirmed large B-cell lymphoma (LBCL)
• Planned treatment with a commercially available anti-CD19 CAR-T product (Yescarta or Kymriah)
• Eligible for and with adequate organ function (investigator discretion) and performance status (ECOG PS 2 or less) for standard of care, anti-CD19 CAR-T
• Not enrolled on a clinical trial of bridging therapy prior to CAR-T
• Patients must have a PET/CT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra- nodal lesions in largest dimension by low-dose computerized tomography [CT] scan with FDG-uptake ≥ liver) documented prior to leukapheresis for CAR-T manufacturing
• Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator
• Can provide informed consent
• Willing to comply with all study procedures and available for the duration of the study

Exclusion criteria

• Subject is pregnant or breast feeding
• History of allergy to energy drinks
• History of inflammatory bowel disease
• History of type 1 diabetes mellitus or requirement for insulin
• History of chronic kidney disease with an eGFR < 30 mL/min/1.73m2
• Additional second primary malignancy for which the subject is receiving active therapy or that will impede the ability of the investigator to assess lymphoma response